This is a monocentre randomized pilot study. All patients received two consecutive RRT: CVVHD with MCO filter (Ultraflux® EMiC®2) and post-Continuous Veno-Venous Hemodiafiltration (CVVHDF) with HFF(AV1000S®) in a controlled randomized (1:1) blinded manner. Crossover randomized to sequence (A+B or B+A) for 48 h total without washout.
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
improvement in haemodynamic parameters
Timeframe: 48 hours
improvement in haemodynamic parameters
Timeframe: 48 hours
improvement in haemodynamic parameters
Timeframe: 48 hours
improvement in haemodynamic parameters
Timeframe: 48 hours
improvement in haemodynamic parameters
Timeframe: 48 hours
improvement in haemodynamic parameters
Timeframe: 48 hours
improvement in haemodynamic parameters
Timeframe: 48 hours
improvement in haemodynamic parameters
Timeframe: 48 hours
improvement in haemodynamic parameters
Timeframe: 48 hours